olmesartan has been researched along with rosuvastatin in 1 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (rosuvastatin) | Trials (rosuvastatin) | Recent Studies (post-2010) (rosuvastatin) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 37 | 0 | 15 |
| Protein | Taxonomy | olmesartan (IC50) | rosuvastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0045 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0032 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, N; Maeda, K; Moriwaki, T; Nakakariya, M; Ono, M; Sugiyama, Y | 1 |
1 other study(ies) available for olmesartan and rosuvastatin
| Article | Year |
|---|---|
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Lactams; Biliary Tract; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Topotecan | 2012 |